Lenalidomida Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to reduced growth of malignant plasma cells, inhibition of new blood‑vessel formation, and enhanced immune‑mediated tumor cell killing.

The specific dose and schedule of Lenalidomida Zentiva are determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Dosing information is provided in the prescribing information and should not be altered without medical guidance.

Lenalidomida Zentiva is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while taking the medication.

To request Lenalidomida Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Lenalidomide is a second‑generation immunomodulatory imide drug (IMiD) and is generally more potent and better tolerated than thalidomide, the first‑generation IMiD. Compared with pomalidomide, another newer IMiD, lenalidomide has a longer history of use in multiple myeloma and del(5q) MDS, though pomalidomide may be preferred in certain refractory cases.

Store Lenalidomida Zentiva tablets at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains tightly closed until use.

Lenalidomida Zentiva is taken orally as a tablet. It can be swallowed with or without food, according to the prescribing physician’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without consultation.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding; venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism; and the possible development of secondary primary malignancies. Prompt medical attention is required if any of these events occur.

Lenalidomida Zentiva should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made under medical supervision. It is also contraindicated in patients receiving live vaccines due to impaired immune response.